Teva (TEVA) Pharmaceuticals announced the launch of ‘The Other TD,’ a disease education campaign leveraging the broad recognition of football touchdowns to raise awareness and understanding of a ...

The double-blind, placebo-controlled Phase II trial is enrolling approximately 100 adult participants with tardive dyskinesia ...

Evoke Pharma, Inc. announced that an abstract comparing the incidence of tardive dyskinesia (TD) in patients undergoing continuous versus intermittent oral metoclopramide treatment has been accepted ...

Tardive dyskinesia (TD) is a movement disorder. It’s a side effect of taking neuroleptic drugs. Treatment is focused on stopping the recurrence or persistence of symptoms. Tardive dyskinesia (TD) is a ...

SAN DIEGO, Aug. 29, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) (Nasdaq: NBIX) today presented findings from a data analysis of KINECT ®-4 demonstrating a comparable pattern of ...

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 2 clinical study of investigational compound NBI-1065890 in adults with tardive dyskinesia (TD). NBI-1065890 is ...

—The exact pathology of tardive dyskinesia is still unclear, but the potential genetic factors these investigators have identified may enhance the understanding, treatment, and prevention of this ...

(RTTNews) - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced results from a study of treatment patterns among patients with tardive dyskinesia (TD) ...

The KINECT-PRO™ analysis is the first and only of its kind to report both remission of tardive dyskinesia symptoms and associated improvements in patient-reported outcomes. Post-hoc analysis from ...